{
  "study_id": "NEJMoa1612674",
  "study_title": "Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer",
  "table_name": "Table 1.",
  "table_title": "Demographic and Clinical Characteristics of the Patients at Baseline.",
  "footnotes": [
    "CNS denotes central nervous system, EGFR epidermal growth factor receptor, and TKI tyrosine kinase inhibitor.",
    "Race was self-reported. The category of “other” includes black, American Indian, and Alaska Native.",
    "CNS metastases were determined from baseline data for the CNS lesion site, medical history, surgery, or radiotherapy. One patient was identified as having locally advanced disease in the brain.",
    "Extrathoracic visceral metastases were determined on the basis of baseline data for which the disease site was described as adrenal, ascites, brain or CNS, gastrointestinal, genitourinary, hepatic (including gallbladder), liver, other CNS, pancreas, peritoneum, or spleen. Also included were other metastatic sites, such as those occurring in the eye and thyroid, as identified as extrathoracic visceral sites by AstraZeneca physicians.",
    "EGFR mutations were identified by means of the cobas EGFR Mutation Test from a biopsy sample obtained after confirmation of disease progression while the patient was receiving the most recent treatment regimen.",
    "Six patients (four in the osimertinib group and two in the platinum–pemetrexed group) did not have centrally confirmed T790M mutation-positive status that was documented in the trial database. Three patients (two in the osimertinib group and one in the platinum–pemetrexed group) were subsequently found to have positive results on testing for the T790M mutation. Therefore, three patients (two in the osimertinib group and one in the platinum–pemetrexed group) were T790M-negative in the tumor sample and underwent randomization in error. One of the three patients who had T790M-negative results in the tumor sample had T790M-positive results in plasma.",
    "Patients were classified as having received more than one previous line of therapy if they received any of the following: adjuvant or neoadjuvant chemotherapy administered less than 6 months before the start of EGFR-TKI therapy; more than one EGFR-TKI (switching from a first-generation EGFR-TKI to a second-generation EGFR-TKI, or restarting EGFR-TKI after >12 months off treatment) administered sequentially; or the addition of anticancer agents such as cytotoxic chemotherapy or a c-Met monoclonal antibody toward the end of a previous monotherapy EGFR-TKI regimen.",
    "One patient in the osimertinib group was treated with fulvestrant followed by letrozole before starting EGFR-TKI."
  ],
  "groups": [
    {
      "name": "Osimertinib",
      "n": 279
    },
    {
      "name": "Platinum-Pemetrexed",
      "n": 140
    }
  ],
  "characteristics": [
    {
      "original_label": "Median age (range) — yr",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "iqr_min": 25.0,
          "iqr_max": 85.0,
          "raw_string": "62 (25–85)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "numeric_median_iqr",
          "median": 63.0,
          "iqr_min": 20.0,
          "iqr_max": 90.0,
          "raw_string": "63 (20–90)"
        }
      ]
    },
    {
      "original_label": "Female sex — no. (%)",
      "standardized_name": "Sex",
      "unit": "participants",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 172.0,
          "percentage": 62.0,
          "raw_string": "172 (62)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 97.0,
          "percentage": 69.0,
          "raw_string": "97 (69)"
        }
      ]
    },
    {
      "original_label": "Race — no. (%)",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "White",
      "unit": "participants",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 89.0,
          "percentage": 32.0,
          "raw_string": "89 (32)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 45.0,
          "percentage": 32.0,
          "raw_string": "45 (32)"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "Asian",
      "unit": "participants",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 182.0,
          "percentage": 65.0,
          "raw_string": "182 (65)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 92.0,
          "percentage": 66.0,
          "raw_string": "92 (66)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other race",
      "unit": "participants",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 3.0,
          "raw_string": "8 (3)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 (2)"
        }
      ]
    },
    {
      "original_label": "No history of smoking — no. (%)",
      "standardized_name": "Smoking status (Never)",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 189.0,
          "percentage": 68.0,
          "raw_string": "189 (68)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 94.0,
          "percentage": 67.0,
          "raw_string": "94 (67)"
        }
      ]
    },
    {
      "original_label": "Disease classification — no. (%)",
      "standardized_name": "Disease classification",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Adenocarcinoma histology not otherwise specified",
      "standardized_name": "Adenocarcinoma histology not otherwise specified",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease classification",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 232.0,
          "percentage": 83.0,
          "raw_string": "232 (83)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 122.0,
          "percentage": 87.0,
          "raw_string": "122 (87)"
        }
      ]
    },
    {
      "original_label": "Metastatic disease",
      "standardized_name": "Metastatic disease",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 266.0,
          "percentage": 95.0,
          "raw_string": "266 (95)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 138.0,
          "percentage": 99.0,
          "raw_string": "138 (99)"
        }
      ]
    },
    {
      "original_label": "CNS metastases",
      "standardized_name": "Central nervous system metastases",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 93.0,
          "percentage": 33.0,
          "raw_string": "93 (33)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 36.0,
          "raw_string": "51 (36)"
        }
      ]
    },
    {
      "original_label": "Extrathoracic visceral metastases",
      "standardized_name": "Extrathoracic visceral metastases",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 145.0,
          "percentage": 52.0,
          "raw_string": "145 (52)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 80.0,
          "percentage": 57.0,
          "raw_string": "80 (57)"
        }
      ]
    },
    {
      "original_label": "Type of EGFR mutation — no. (%)",
      "standardized_name": "EGFR mutation type",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "T790M",
      "standardized_name": "T790M mutation",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation type",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 275.0,
          "percentage": 99.0,
          "raw_string": "275 (99)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 138.0,
          "percentage": 99.0,
          "raw_string": "138 (99)"
        }
      ]
    },
    {
      "original_label": "Exon 19 deletion",
      "standardized_name": "Exon 19 deletion",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation type",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 191.0,
          "percentage": 68.0,
          "raw_string": "191 (68)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 87.0,
          "percentage": 62.0,
          "raw_string": "87 (62)"
        }
      ]
    },
    {
      "original_label": "Exon 21 L858R",
      "standardized_name": "Exon 21 L858R",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation type",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 83.0,
          "percentage": 30.0,
          "raw_string": "83 (30)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 45.0,
          "percentage": 32.0,
          "raw_string": "45 (32)"
        }
      ]
    },
    {
      "original_label": "G719X",
      "standardized_name": "G719X mutation",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation type",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.0,
          "raw_string": "4 (1)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.0,
          "raw_string": "2 (1)"
        }
      ]
    },
    {
      "original_label": "S768I",
      "standardized_name": "S768I mutation",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation type",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.0,
          "raw_string": "1 (<1)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.0,
          "raw_string": "1 (1)"
        }
      ]
    },
    {
      "original_label": "Exon 20 insertion",
      "standardized_name": "Exon 20 insertion",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation type",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.0,
          "raw_string": "1 (<1)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.0,
          "raw_string": "2 (1)"
        }
      ]
    },
    {
      "original_label": "No. of previous anticancer regimens for advanced disease — no. (%)",
      "standardized_name": "Number of previous anticancer regimens",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "1",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of previous anticancer regimens",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 269.0,
          "percentage": 96.0,
          "raw_string": "269 (96)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 134.0,
          "percentage": 96.0,
          "raw_string": "134 (96)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "2",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of previous anticancer regimens",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 3.0,
          "raw_string": "9 (3)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 4.0,
          "raw_string": "6 (4)"
        }
      ]
    },
    {
      "original_label": "3",
      "standardized_name": "3",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of previous anticancer regimens",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.0,
          "raw_string": "1 (<1)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0"
        }
      ]
    },
    {
      "original_label": "Previous EGFR-TKI therapy — no. (%)",
      "standardized_name": "Received previous EGFR-TKI therapy",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 279.0,
          "percentage": 100.0,
          "raw_string": "279 (100)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 139.0,
          "percentage": 99.0,
          "raw_string": "139 (99)"
        }
      ]
    },
    {
      "original_label": "Gefitinib",
      "standardized_name": "Gefitinib",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Received previous EGFR-TKI therapy",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 166.0,
          "percentage": 59.0,
          "raw_string": "166 (59)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 87.0,
          "percentage": 62.0,
          "raw_string": "87 (62)"
        }
      ]
    },
    {
      "original_label": "Erlotinib",
      "standardized_name": "Erlotinib",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Received previous EGFR-TKI therapy",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 96.0,
          "percentage": 34.0,
          "raw_string": "96 (34)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 49.0,
          "percentage": 35.0,
          "raw_string": "49 (35)"
        }
      ]
    },
    {
      "original_label": "Afatinib",
      "standardized_name": "Afatinib",
      "unit": "participants",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Received previous EGFR-TKI therapy",
      "group_data": [
        {
          "group_name": "Osimertinib",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 7.0,
          "raw_string": "20 (7)"
        },
        {
          "group_name": "Platinum-Pemetrexed",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 3.0,
          "raw_string": "4 (3)"
        }
      ]
    }
  ]
}